#Bharat Biotech – Asian Mirror

December 28, 2022 by: web admin

iNCOVACC to be available in January as booster dose

ANS: iNCOVACC— nasal vaccine against Covid-19 would be available in the market for the public from the fourth week of January. Bharat Biotech, Hyderabad-based Biotechnology …

December 23, 2022 by: web admin

‘iNCOVACC’ gets Govt. nod as booster shot

ANS: The intranasal Covid-19 vaccine— iNCOVACC (BBV154), developed by Bharat Biotech, received approval from the ministry of health on Friday to be added to the …

April 9, 2022 by: web admin

Covishield, Covaxin price cuts to Rs 225 per dose for private hospitals

ANS: The prices of Covid vaccine, COVISHIELD (Serum Institute) and COVAXIN (Bharat Biotech) have been slashed for private hospitals. The price of the Covishield vaccine …

January 5, 2022 by: web admin

Intranasal vaccine gets nod for Phase 3 trials in India

ANS: The subject expert committee (SEC) of Drugs controller General of India (DCGI) has recommended that Hyderabad-based Bharat Biotech can conduct phase- three trials on …

November 3, 2021 by: web admin

Bharat Biotech’s Covaxin gets WHO approval for emergency use

ANS: World Health Organisation (WHO) granted approval to India’s first indigenous COVID-19 vaccine– Covaxin– for emergency use listing (EUL) for COVID-19 on Wednesday. The Technical …

August 6, 2021August 6, 2021 by: web admin

COVID jab for kids by Q1 of 2022: Poonawalla

JNS: Covovax, another COVID-19 vaccine, being manufactured by Serum Institute of India, will be launched in October for adults and for children by the first quarter …

May 16, 2021 by: web admin

Govt. to increase Covaxin production 1mn per month by Sept. 21

ANS: The Central Government is mulling to increase the production of indigenously developed Covaxin— COVID-19 vaccine to approximately 1 million doses per month. Presently Bharat …

May 12, 2021 by: web admin

Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds

ANS: An expert panel on Tuesday recommended Covaxin (COVID-19 vaccine) for phase-2 and phase-3 clinical trial on younger population aged between 2 to 18 years, …

April 29, 2021 by: web admin

Covaxin found to neutralise 617 variant of Coronavirus

ANS: Covaxin, has been found to neutralise Double Mutant or 617 variant of the Corona virus, said Dr Anthony Fauci, White House chief medical adviser …

April 22, 2021 by: web admin

Covaxin 100% effective against severe COVID-19: ICMR-Bharat Biotech

ANS: Covaxin, a coronavirus vaccine, developed in India by a Hyderabad-based company- Bharat Biotech, has reported overall interim clinical efficacy of 78 per cent, said …

Apple to Double iPhone Production in India with Massive Factory Expansion

Apple to Double iPhone Production in India with Massive Factory Expansion

Tag: #Bharat Biotech

iNCOVACC to be available in January as booster dose

‘iNCOVACC’ gets Govt. nod as booster shot

Covishield, Covaxin price cuts to Rs 225 per dose for private hospitals

Intranasal vaccine gets nod for Phase 3 trials in India

Bharat Biotech’s Covaxin gets WHO approval for emergency use

COVID jab for kids by Q1 of 2022: Poonawalla

Govt. to increase Covaxin production 1mn per month by Sept. 21

Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds

Covaxin found to neutralise 617 variant of Coronavirus

Covaxin 100% effective against severe COVID-19: ICMR-Bharat Biotech